A phase 2, open-label investigator-initiated study of MWPC005 in non-melanoma skin cancer
Latest Information Update: 02 Dec 2021
At a glance
- Drugs MWPC 005 (Primary)
- Indications Actinic keratosis; Basal cell cancer; Desquamation; Skin cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Nov 2021 According to a MediWound media release, data from this study expected first half of 2022.
- 10 Aug 2021 Status changed from planning to recruiting, according to a MediWound media release.
- 25 Feb 2021 New trial record